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Previewsand whether these interactions are in turn
influenced by PAR formation.
With these new findings, a comprehen-
sive and satisfying picture has emerged to
account for the biphasic pattern of
BRCA1 assembly at DSBs (Figure 1). In
this scenario, the BRCA1/BARD1 hetero-
dimer is rapidly recruited to DSB ends in
an H2AX-independent manner by virtue
of the interaction of its BARD1 BRCT
domain with PAR. Subsequently, the het-
erodimer associates in a more durable
fashion with the flanking DSB chromatin
through the well-defined gH2AX pathway
upon interaction of its BRCA1 BRCT
domain with phosphorylated Abraxas. It
is important to note that the vast majority
of BRCA1 and BARD1 mutations asso-
ciated with hereditary breast cancer are
either (1) truncating or missense muta-
tions that ablate BRCT phospho-recogni-
tion or (2) missense mutations that
abolish BRCA1/BARD1 heterodimeri-
zation. Thus, a common denominator of
most tumor-predisposing defects is
disruption of either the early and/or late
pathways of BRCA1/BARD1 recruitment.
A key objective of future studies will be
to determine the specific functions of
BRCA1/BARD1 within each of the two
DSB subcompartments and to ascertain
whether these functions are relevant for
tumor suppression.The exquisite sensitivity of BRCA1-
and BRCA2-defective tumors to PARP
inhibitors was originally thought to
reflect a synthetic lethal effect whereby
BRCA1/2 mutant cells, which are intrinsi-
cally defective for DSB repair, are
rendered inviable by simultaneous inacti-
vation of single-strand DNA break repair,
which is normally dependent on PARP1
(Rouleau et al., 2010). However, recent
studies suggest that this model is
incomplete and that other actions of
PARP may also be relevant (Helleday,
2011). As noted by Li and Yu (2013),
most BRCA1-deficient tumors have le-
sions of the BRCA1 BRCT domains
that would disrupt the late gH2AX-
dependent, but not the early PAR-
dependent, pathway of BRCA1/BARD1
recruitment. Thus, the heightened sensi-
tivity of these cells to PARP inhibition
might reflect the fact that both modes
of BRCA1/BARD1 recruitment are abla-
ted simultaneously. As such, this work
may have important clinical implications
for the anti-cancer activity of PARP
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Widespread structural alterations of cancer genomes are increasingly observed in a broad spectrum of
tumors. In a recent issue of Cell, Baca and colleagues describe large chains of rearrangements that co-
ordinately affect multiple chromosomes in prostate cancer. This phenomenon of chromoplexy may define
cancer subtypes and drive punctuated tumor evolution.The application of next-generation
sequencing technologies has resulted in
systematic efforts to characterize the
mutational spectrum, genomic alter-ations, and clonal evolution of a wide
range of tumors. In particular, whole-
genome sequencing approaches can
reveal extensive structural rearrange-ments throughout the tumor genome,
which can be difficult to detect using
more limited exome sequencing appro-
aches. The whole-genome sequencingl 23, May 13, 2013 ª2013 Elsevier Inc. 567
Figure 1. Comparison of Chromoplexy and Chromothripsis
Schematic representations show chromosomal rearrangements that occur in tumor genomes as a conse-
quence of chromoplexy (top) or chromothripsis (bottom).
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Previewsanalysis of prostate tumors by Baca et al.
(2013) represents the most com-
prehensive analysis to date for one of
the most common human malignancies,
resulting in a surprising new insight into
cancer genomes.
Prostate cancer was the first solid
tumor shown to have frequent large-
scale chromosomal rearrangements, as
originally demonstrated by the discovery
of the TMPRSS2-ERG fusion (Tomlins
et al., 2005). Subsequent studies have
shown that chromosomal rearrange-
ments and extensive copy number alter-
ations are prevalent in prostate cancer,
whereas point mutations are relatively
infrequent, suggesting that structural al-
terations in tumor genomes represent
the primary drivers of prostate cancer
progression (Barbieri et al., 2012; Rubin
et al., 2011; Taylor et al., 2010). Further-
more, previous whole-genome sequenc-
ing of seven prostate tumors showed
frequent occurrence of complex chains
of balanced rearrangements, involving
both intrachromosomal and interchro-
mosomal events (Berger et al., 2011).
In the current study, Baca et al. (2013)
performed whole-genome sequencing
analysis of 57 prostate tumors and identi-
fied 5,596 somatic rearrangements.
Notably, almost 40% of the detected
rearrangements were components of
complex and lengthy series of rearrange-
ments, often occurring as closed chains.
Such chained rearrangements could
display precise or nearly precise joins
at their breakpoints or alternatively were
associated with large DNA deletions at568 Cancer Cell 23, May 13, 2013 ª2013 Elstheir junctions, corresponding to ‘‘deletion
bridges.’’ The number of rearrangements
within a chain was highly variable, ranging
from 3 to over 40, with six or more chro-
mosomes possibly involved. Nearly 90%
of the tumors contained chains with five
or more rearrangements, and more than
60% of the tumors contained more than
one such chain. Importantly, statistical an-
alyses indicated that such rearrange-
ments are unlikely to arise independently,
and instead may form in a coordinated
and simultaneous fashion. Thus, Baca
et al. (2013) coin the term ‘‘chromoplexy’’
to describe this phenomenon of intricately
weaved genomic rearrangements occur-
ring in concert (Figure 1).
Chromoplexy can account for many of
the known genomic alterations found
in prostate cancer by generation of
oncogenic fusion genes as well as by
disruption or deletion of genes located
near rearrangement breakpoints (Baca
et al., 2013). Although no novel recurrent
rearrangements were discovered in this
analysis, the TMPRSS2-ERG fusion was
often found as part of chromoplectic
rearrangement chains. Moreover, puta-
tive oncogenic fusions involving BRAF
and MAPK1 were uniquely identified in
individual tumors, while loss-of-function
alterations due to chromoplexy for the
putative tumor suppressor genes PTEN,
NKX3.1, TP53, and CDKN1B were ob-
served in multiple tumors. In particular,
several tumors contained evidence for
multiple loss- and gain-of-function alter-
ations occurring in the context of a single
chromoplectic event.evier Inc.The coordinated structural rearrange-
ments characteristic of chromoplexy
exhibit features similar to but distinct
from the phenomenon of chromothripsis
that has been observed in a diverse
range of malignancies (Figure 1) (Forment
et al., 2012; Jones and Jallepalli, 2012).
Both chromothripsis and chromoplexy
display random breakage and fusion of
genomic segments with low copy number
states, most likely mediated by non-
homologous end-joining. However, the
genomic breakpoints associated with
chromothripsis typically number in the
hundreds and are locally clustered within
one or two chromosomes, whereas the
chained rearrangements characteristic
of chromoplexy are unclustered, usually
number in the tens, and include multiple
chromosomes. Furthermore, chromo-
thripsis appears to occur as a single
clonal event early in tumor progression,
while chromoplexy can occur more than
once in prostate cancer evolution, with
sequential events detected at clonal or
subclonal frequencies. Finally, chromo-
thripsis represents a relatively infrequent
event for all tumor types analyzed to
date, whereas chromoplexy is a common
event in prostate cancer. Nonetheless,
the distinction between chromothripsis
and chromoplexy is not well defined,
and it is conceivable that some coordi-
nated structural rearrangements may
have intermediate properties.
Distinct molecular mechanisms are
likely to underlie chromothripsis versus
chromoplexy. Although several models
have been advanced to explain the mech-
anistic basis for chromothripsis, major
causes are likely to be replication stress
and mitotic errors, perhaps in association
with the formation of micronuclei and
premature chromosome compaction
(Forment et al., 2012; Jones and Jallepalli,
2012). Notably, micronucleus formation is
a characteristic feature of genomic insta-
bility, and loss of p53 appears to result
in increased frequency of chromothripsis.
In contrast, the mechanistic basis of
chromoplexy is less well understood at
present, but may be causally related to
DNA damage induced by transcription
factor binding. Previous studies have
shown that formation of the TMPRSS2-
ERG fusion in tumor cell lines is mediated
by double-strand breaks induced by
binding of androgen receptor (AR), and
can be facilitated by genotoxic stress
Cancer Cell
Previews(Haffner et al., 2010; Rubin et al., 2011).
Consistent with such a model, chro-
moplectic rearrangement breakpoints
are associated with active transcription
and open chromatin configurations
(Baca et al., 2013).
The study by Baca et al. (2013) also
sheds light on potential molecular sub-
types of prostate adenocarcinoma.
Despite the existence of categories of
prostate cancer patients with markedly
different survival outcomes, previous
attempts to discern distinct histopatho-
logical or molecular subtypes of prostate
cancer have met with limited success
(Shen and Abate-Shen, 2010). Baca
et al. (2013) now suggest the existence
of at least two distinct molecular subtypes
defined by the presence or absence of the
TMPRSS2-ERG fusion (ETS+) and by the
mutational status of CHD1, which en-
codes a chromodomain helicase involved
in chromatin remodeling. Whereas rear-
rangements occurring in ETS+ CHD1WT
tumors are predominantly interchro-
mosomal and display features of chro-
moplexy, ETS CHD1del tumors display
a higher frequency of intrachromosomal
rearrangements, which more closely
resemble chromothripsis. Moreover, the
rearrangement breakpoints in ETS+
CHD1WT tumors tend to occur near
highly expressed loci, consistent with
a transcription-associated mechanism
for chromoplexy, but the ETS CHD1del
tumors instead contain rearrangements
that are often associated with hetero-
chromatin. Whether these molecularlydistinct groups correspond to distinct
patient outcomes and/or treatment re-
sponses will undoubtedly represent a
major issue for future studies.
Although chromoplexy appears to be a
cardinal feature of many prostate tumor
genomes, it is currently unclear whether
it plays a key role in other cancer types.
Interestingly, Baca et al. (2013) detect
chained rearrangements in a significant
proportion of non-small cell lung cancers,
head and neck cancers, and melanomas,
suggesting that chromoplexy can also
occur in a broad spectrum of tumors.
Given the apparent central role of AR
and possibly ETS transcription factors in
promoting chromoplexy in prostate tu-
mors, it will be interesting to determine
whether the chromoplectic events found
in other cancers are qualitatively similar
or distinct.
Overall, chromoplexy and chromothrip-
sis undoubtedly represent key drivers of
tumor evolution. In contrast to traditional
‘‘gradualist’’ views of sequential accu-
mulation of cancer-promoting mutations,
the large-scale structural alterations of
both chromoplexy and chromothripsis
are likely to promote discontinuous
tumor evolution in a form of ‘‘punctuated
equilibrium’’ (Baca et al., 2013). More-
over, further discrete steps in tumor
evolution can potentially arise through
the sequential occurrence of chro-
mothripsis followed by chromoplexy or
by successive rounds of chromoplexy.
Modeling the causes and consequences
of such genomic alterations will be aCancer Celserious issue for cancer biologists, while
their impact on treatment response and
resistance will pose significant clinical
challenges.REFERENCES
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